|
gptkbp:instance_of
|
gptkb:fragrance
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:abemaciclib
|
|
gptkbp:activities
|
inhibits aromatase enzyme
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1995
gptkb:FDA
|
|
gptkbp:associated_with
|
increased risk of osteoporosis
increased bone density loss
lower estrogen levels
|
|
gptkbp:brand
|
Arimidex
|
|
gptkbp:can_be_used_with
|
other hormonal therapies
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
gptkb:tablet
1 mg daily
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
anastrozole
|
|
gptkbp:ingredients
|
C17 H19 N5
|
|
gptkbp:interacts_with
|
gptkb:tamoxifen
estrogen
|
|
gptkbp:invention
|
gptkb:2012
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_monitored_by
|
regular liver function tests
regular bone density tests
regular cholesterol tests
|
|
gptkbp:is_used_for
|
breast cancer treatment
|
|
gptkbp:lifespan
|
50 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
many countries
|
|
gptkbp:provides_information_on
|
NCCN guidelines
|
|
gptkbp:research_focus
|
gptkb:hormone_receptor-positive_breast_cancer
|
|
gptkbp:side_effect
|
gptkb:historical_event
gptkb:fandom
fatigue
nausea
cardiovascular issues
joint pain
thromboembolic events
dry skin
insomnia
weight gain
headaches
skin rash
mood changes
hot flashes
memory issues
nail changes
hair thinning
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:suitable_for
|
pre-menopausal women
|
|
gptkbp:targets
|
estrogen production
|
|
gptkbp:used_in
|
adjuvant therapy
metastatic breast cancer
|
|
gptkbp:weight
|
293.36 g/mol
|